Effects of Shuxuetong Injection on Related Indexes of Patients with Acute Myocardial Infarction
10.6039/j.issn.1001-0408.2017.24.17
- VernacularTitle:疏血通注射液对急性心肌梗死患者相关指标的影响
- Author:
Chaoyang TAN
;
Dawei LIU
- Keywords:
Shuxuetong injection;
Urokinase;
Aspirin;
Clopidogrel;
Acute myocardial infarction;
Heart function;
Safety
- From:
China Pharmacy
2017;28(24):3374-3376
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the effects of Shuxuetong injection on related indexes of patients with acute myocardial infarction (AMI).METHODS:The data of 156 AMI patients were analyzed retrospectively,and then divided into control group (65 cases) and observation group (91 cases) according to therapy plan.Control group received routine treatment.Observation group was additionally given Shuxuetong injection 6 mL added into 5％ Glucose injection 250 mL intravenously,once a day,on the basis of control group.Both groups were given treatment for 5 d.The incidence of vascular recanalization,recanalization time,the incidence of reocclusion as well as LVEF,APTT,PT,FIB,the occurrence of adverse cardiovascular events before and after treatment as well as the occurrence of ADR were observed in 2 groups.RESULTS:The incidence of reocclusion and adverse cardiovascular events in observation group was significantly lower than control group,with statistical significance (P＜0.05).There was no statistical significance in the incidence of vascular recanalization,recanalization time or the incidence of ADR between 2 groups (P＞0.05).After treatment,the levels of LVEF,APTT and PT in 2 groups were significantly higher than before treatment,and the observation group was significantly higher than the control group.The levels of FIB in 2 groups were significantly lower than before treatment,and the observation group was significantly lower than the control group,with statistical significance (P＜0.05).CONCLUSIONS:Based on routine treatment,Shuxuetong injection can reduce the incidence of reocclusion,improve cardiac function and reduce the incidence of adverse cardiovascular events without increasing the occurrence of ADR.
